[Proteolytic enzymes and their inhibitors in clinical and experimental oncology].
D000818:Animals; D007611:Aprotinin / Q000627:therapeutic use; D001943:Breast Neoplasms / Q000201:enzymology; D002401:Cathepsin B; D002403:Cathepsins / Q000378:metabolism; D002471:Cell Transformation, Neoplastic; D005260:Female; D006801:Humans; D007822:Laryngeal Neoplasms / Q000201:enzymology; D008175:Lung Neoplasms / Q000201:enzymology; D051379:Mice; D009369:Neoplasms / Q000188:drug therapy / Q000201:enzymology*; D010051:Ovarian Neoplasms / Q000201:enzymology; D010190:Pancreatic Neoplasms / Q000201:enzymology; D010436:Pepstatins / Q000627:therapeutic use; D010447:Peptide Hydrolases / Q000378:metabolism*; D011480:Protease Inhibitors / Q000627:therapeutic use*; D051381:Rats; D013274:Stomach Neoplasms / Q000201:enzymology; D000515:alpha 1-Antitrypsin / Q000378:metabolism
D010436:Pepstatins; D011480:Protease Inhibitors; D000515:alpha 1-Antitrypsin; C014195:Streptomyces pepsin inhibitor; D007611:Aprotinin; D002403:Cathepsins; D010447:Peptide Hydrolases; D002401:Cathepsin B; C031375:pepstatin
Proteoliticheskie fermenty i ikh ingibitory v klinicheskoĭ i éksperimental'noĭ onkologii.